Alpha Tau Medical (DRTS) Stock Price, News & Analysis

Company Overview

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors. Alpha DaRT implants release alpha-emitting atoms that diffuse a few millimeters into the tumor, providing localized radiation doses that have shown promising preclinical and early clinical anti‐tumor activity. Alpha Tau Medical has secured Breakthrough Device designation from the U.S. Food and Drug Administration for certain cancer types and is advancing its pipeline through multi‐center trials in Europe and Israel.

Alpha Tau Medical collaborates with major oncology centers and academic institutions to conduct its clinical programs and to explore combination approaches with immunotherapies and other treatment modalities. The company has expanded its operational footprint beyond Israel, engaging regulatory and commercial partners in Europe while preparing for potential U.S. market entry. Through its focused R&D efforts and strategic alliances, Alpha Tau Medical seeks to establish alpha‐particle brachytherapy as a new standard of care for patients with challenging solid tumors.

Key Stats

• Today's Range: $14.14 to $14.52
• 50-Day Range: $9.19 to $14.50
• 52-Week Range: $3.00 to $14.75
• Volume: 314,195 shs
• Average Volume: 591,683 shs
• Market Capitalization: $1.29 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.80
• Consensus Rating: Moderate Buy

Alpha Tau Medical Stock Analysis - MarketRank™

Alpha Tau Medical scored higher than 27% of companies evaluated by MarketBeat, and ranked 798th out of 913 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Alpha Tau Medical has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 5 buy ratings, 2 hold ratings, and 1 sell rating.

Downside Risk

Alpha Tau Medical has a consensus price target of $12.80, representing about 10.2% downside from its current price of $14.25.

Amount of Analyst Coverage

Alpha Tau Medical has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Alpha Tau Medical are expected to grow in the coming year, from ($0.92) to ($0.53) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Alpha Tau Medical is -13.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Alpha Tau Medical is -13.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Alpha Tau Medical has a P/B Ratio of 16.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.87% of the float of Alpha Tau Medical has been sold short.

Short Interest Ratio / Days to Cover

Alpha Tau Medical has a short interest ratio ("days to cover") of 5.03.

Change versus previous month

Short interest in Alpha Tau Medical has recently increased by 7.63%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Alpha Tau Medical does not currently pay a dividend.

Dividend Growth

Alpha Tau Medical does not have a long track record of dividend growth.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.05

News Sentiment

Alpha Tau Medical has a news sentiment score of 0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 26 news articles for Alpha Tau Medical this week, compared to 4 articles on an average week.

MarketBeat Follows

3 people have added Alpha Tau Medical to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Alpha Tau Medical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,519,143.00 in company stock.

Percentage Held by Insiders

39.50% of the stock of Alpha Tau Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

2.65% of the stock of Alpha Tau Medical is held by institutions.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 8/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:DRTS
• CIK: 1871321
• Web: healthcarecapitalcorp.com
• Phone: 972-3577-4115
• Fax: N/A
• Employees: 80
• Year Founded: 2016

Price Target and Rating

• Average Price Target for Alpha Tau Medical: $12.80
• High Price Target: $17.00
• Low Price Target: $8.00
• Potential Upside/Downside: -10.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.04)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$42.63 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -138.12%
• Return on Assets: -81.68%

Debt

• Debt-to-Equity Ratio: 0.15
• Current Ratio: 11.09
• Quick Ratio: 7.79

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.49 per share
• Price / Book: 29.08

Miscellaneous

• Outstanding Shares: 90,330,000
• Free Float: 54,647,000
• Market Cap: $1.29 billion
• Optionable: No Data
• Beta: 1.17